Dr. Günel, a globally recognized neurobiologist and a leading figure in neurological surgery, has joined Science Corporation as a scientific adviser following two years of intensive discussions and collaboration. His primary objective is to facilitate the surgical placement of the initial sensor component for this pioneering interface into a human patient’s brain. This sensor is designed to eventually integrate with lab-grown neurons, forming a novel biological-electronic bridge that promises to overcome the inherent limitations of conventional BCI systems. The move underscores Science Corporation’s commitment to a distinct technological pathway, differentiating itself from other players in the burgeoning BCI landscape, including Hodak’s former venture, Neuralink.
Science Corporation’s Ascent and Vision
Founded in 2021 by Max Hodak, Science Corporation quickly established itself as a formidable entity in the neurotechnology sector. The company recently announced the successful completion of a $230 million Series C fundraising round last month, elevating its valuation to an impressive $1.5 billion. This substantial investment reflects strong investor confidence in Hodak’s vision and the company’s technological prowess, particularly its dual focus on immediate therapeutic applications and long-term neuro-enhancement.
While the biohybrid BCI represents Science Corporation’s most ambitious long-term project, the company is also making significant strides with its more advanced product, PRIMA. PRIMA is a state-of-the-art device engineered to restore vision in individuals suffering from blindness caused by conditions such as macular degeneration. Science Corporation acquired this promising technology in 2024 and has since rapidly advanced it through rigorous clinical trials. The company anticipates securing regulatory approval in Europe as early as this year, paving the way for wider availability and offering hope to millions affected by degenerative eye conditions. Macular degeneration alone affects an estimated 11 million people in the United States and is a leading cause of vision loss among older adults globally, highlighting the significant market and humanitarian impact of PRIMA.
However, Hodak’s overarching vision for Science Corporation extends far beyond restoring lost senses. From the outset, he co-founded the company with a profound ambition: to forge reliable, high-bandwidth communication links between computers and the human brain. This grand objective encompasses both the treatment of severe neurological diseases and the audacious pursuit of human enhancement, including the potential to introduce entirely new sensory modalities to the human body. Hodak’s career trajectory has consistently pointed towards this proposition, from his early days talking his way into a graduate neuroscience lab as a college student, through founding his first biotech computing startup, to his prominent role in establishing Neuralink alongside entrepreneur Elon Musk.
The Limitations of Conventional BCIs and Science’s Biohybrid Alternative
The field of brain-computer interfaces has witnessed remarkable progress in recent years, with several organizations, including Neuralink, achieving significant milestones. These advancements have primarily involved the use of electronic sensors to detect and interpret brain activity in patients afflicted by conditions such as amyotrophic lateral sclerosis (ALS), spinal cord injuries, and other neurological disorders that sever the brain’s communication pathways with the body. Patients with implanted devices have demonstrated the ability to control computer cursors, operate robotic limbs, or generate text on a screen merely through their thoughts. These breakthroughs offer profound improvements in quality of life for individuals with severe disabilities.
Despite these successes, the path to widespread commercialization and market penetration for traditional BCI devices remains fraught with challenges. Regulatory hurdles are substantial, given the invasive nature of many implants and the long-term safety considerations. Furthermore, the relatively small number of patients with diagnoses suitable for current BCI applications limits the immediate market size, posing economic viability questions for some developers.
A more fundamental challenge, according to Hodak and corroborated by Dr. Günel, lies in the inherent limitations of the conventional method of interfacing with the brain using electricity via metal probes or electrodes. While these technologies can yield impressive results in the short term, Dr. Günel points out that such probes inevitably cause micro-damage to brain tissue. This tissue damage, even if subtle initially, is likely to degrade device performance over time due to glial scarring and inflammatory responses, potentially leading to reduced signal quality or even device failure. This critical limitation spurred the Science Corporation founding team to explore a radically different, more organic approach.
"The idea of using natural connections through neurons and creating a biological interface between the electronics and the human brain is genius," Dr. Günel shared in an interview with TechCrunch, emphasizing the paradigm shift embodied by Science Corporation’s technology. This biohybrid philosophy forms the bedrock of their innovation.
The Biohybrid Sensor: A Closer Look
The development of Science Corporation’s pioneering biohybrid sensor has been meticulously led by Alan Mardinly, a co-founder and the company’s chief science officer, alongside a dedicated team of 30 researchers. The final iteration of this groundbreaking device is envisioned to be embedded with lab-grown neurons. These cultivated neurons are designed to be exquisitely sensitive to pulses of light, which will be used to stimulate them. Crucially, these engineered neurons are intended to naturally integrate and form synaptic connections with the existing neurons within a patient’s brain, thereby establishing a true biological bridge between the electronic components of the interface and the intricate neural networks of the brain.
In 2024, the company provided compelling evidence for the feasibility of this approach by releasing a working paper (available on bioRxiv) detailing successful preclinical studies. The paper demonstrated that the biohybrid device could be safely implanted in mice and effectively used to stimulate brain activity. This crucial proof-of-concept validated the core principles of their biohybrid design and laid the groundwork for human translation.
Currently, the internal focus at Science Corporation is concentrated on developing advanced prototypes of the device and refining the complex protocols for growing neuron cells tailored for various therapeutic applications. This process involves ensuring that the lab-grown neurons meet the stringent standards required for medical use, including considerations for purity, viability, and long-term stability within the biological environment.
Paving the Way for Human Trials
Dr. Günel’s role as scientific adviser is multifaceted and critical as Science Corporation prepares for its monumental human clinical trials. He is actively guiding the research team through the intricate planning stages and is already engaged in discussions with the medical ethics boards responsible for overseeing experiments involving human subjects. These boards, often referred to as Institutional Review Boards (IRBs), play a vital role in safeguarding the rights and welfare of participants in clinical research, meticulously reviewing trial protocols for ethical soundness, patient safety, and scientific merit.
The initial phase of human trials will focus on testing the company’s advanced sensor component, specifically without the embedded lab-grown neurons, inside a living human brain. This phased approach allows for a meticulous evaluation of the sensor’s safety, biocompatibility, and efficacy in accurately measuring brain activity before introducing the more complex biohybrid elements.
A notable aspect of Science Corporation’s strategy involves a differentiated approach to regulatory approval compared to other BCI developers. Unlike devices such as those from Neuralink, which are designed for direct insertion into brain tissue (intracortical placement), Science Corporation’s sensor will be implanted inside the skull but will rest on the surface of the brain, specifically on top of the cerebral cortex (an epidural or subdural placement). This less invasive positioning is a key factor in the company’s assertion that it may not require full FDA investigational device exemption (IDE) approval for these initial trials. Science Corporation argues that the tiny device, which packs an impressive 520 recording electrodes into an area roughly the size of a pea, poses no significant risk to patients due to its superficial placement. This regulatory strategy, while potentially accelerating the trial timeline, will undoubtedly be scrutinized by the broader medical and regulatory communities.
The team’s plan for patient recruitment involves identifying candidates who are already scheduled for significant brain surgery for other medical conditions. For instance, stroke victims who require a craniectomy – a surgical procedure where a piece of the skull is removed to alleviate brain swelling and pressure – represent an ideal demographic. In such cases, Dr. Günel anticipates that the sensor can be safely placed on top of their cortex, allowing for a thorough evaluation of its safety, functionality, and ability to accurately measure brain activity in a real-world clinical setting without necessitating an entirely new invasive procedure.
Broad Implications and Future Potential
If the biohybrid device proves successful in clinical trials, Dr. Günel envisions its potential to address a wide spectrum of neurological conditions. In the near term, one of its early applications could involve delivering gentle, targeted electrical stimulation to damaged brain or spinal cord cells to encourage healing and regeneration. Another immediate utility could be in monitoring neurological activity in patients with brain tumors, providing early warnings to caregivers about impending seizures, thereby enhancing patient safety and management.
Looking further ahead, if the full transformative potential of these biohybrid devices is realized, Dr. Günel contemplates their capacity to offer significantly more effective treatments for debilitating conditions such as Parkinson’s disease. Parkinson’s is a progressive neurodegenerative disorder that gradually erodes a patient’s control over their motor functions, leading to tremors, rigidity, and difficulty with movement. It affects over 10 million people worldwide, and current treatment options, while helpful, are largely symptomatic and do not halt disease progression. These include medications, experimental brain cell transplants, and deep brain stimulation (DBS) with implanted electrodes. However, none of these interventions have been definitively proven to reliably stop the relentless advance of the disease.
Dr. Günel expresses profound optimism about the biohybrid system’s potential to transcend current limitations. "I imagine this biohybrid system as combining those two – you have the electronics, and you have the biological system," he explained to TechCrunch. "In Parkinson’s, for example, we cannot stop the progression of the disease; in neurosurgery, all we are doing is putting an electrode to stop the tremors. Whereas if you can really put the [transplanted] cells back in the brain, protect those circuits, there’s a chance, and I believe it’s a good chance, that we can stop progression of the disease." This perspective highlights the fundamental difference between merely managing symptoms and potentially altering the disease course through a more integrated, biologically compatible approach.
The integration of engineered neurons could potentially allow for more precise and sustained therapeutic effects, minimizing the foreign body response and enhancing long-term stability and efficacy, which are critical for chronic conditions like Parkinson’s. This blend of electronic precision and biological integration could unlock unprecedented avenues for neuro-restoration and disease modification.
While the promise is immense, the journey ahead is still extensive. Dr. Günel prudently cautioned that expecting trials to commence as early as 2027 would be "optimistic," underscoring the meticulous planning, rigorous testing, and extensive ethical and regulatory reviews still required. Nevertheless, the involvement of a luminary like Dr. Murat Günel and the innovative biohybrid approach positions Science Corporation at the forefront of a new era in neurotechnology, one that holds the potential to redefine the boundaries of human health and capability. The scientific community and patients awaiting breakthroughs will be closely watching the progress of these groundbreaking trials.
